MétaCan
Menu
Back to cohort
Record W4392366229 · doi:10.4244/eij-d-23-00699

One-month DAPT with ticagrelor and aspirin for patients undergoing coronary artery bypass grafting: rationale and design of the randomised, multicentre, double-blind, placebo-controlled ODIN trial

2024· article· en· W4392366229 on OpenAlexafffund
Sigrid Sandner, Mario Gaudino, Björn Redfors, Dominick J. Angiolillo, Ori Ben‐Yehuda, Deepak L. Bhatt, Stephen E. Fremes, André Lamy, Riccardo Marano, Roxana Mehran, Stuart Pocock, Sunil V. Rao, John A. Spertus, Jonathan W. Weinsaft, George A. Wells, Marc Ruel

Bibliographic record

VenueEuroIntervention · 2024
Typearticle
Languageen
FieldMedicine
TopicAntiplatelet Therapy and Cardiovascular Diseases
Canadian institutionsUniversity of OttawaHealth Sciences CentrePopulation Health Research InstituteUniversity of TorontoSunnybrook Health Science Centre
FundersNational Heart, Lung, and Blood InstituteNational Institutes of HealthIdorsia PharmaceuticalsMedizinische Universität WienSahlgrenska UniversitetssjukhusetUniversità Cattolica del Sacro CuoreUniversity of California, San DiegoUniversity of TorontoAssistance publique-Hôpitaux de ParisSaint Luke's Health SystemRegado BiosciencesCanadian Institutes of Health ResearchLondon School of Hygiene and Tropical MedicineUniversity of Missouri-Kansas CityBoston VA Research InstituteUniversity of OttawaUniversität WienBoston Scientific CorporationDuke Clinical Research InstituteEisaiCytokineticsBristol-Myers SquibbCleveland ClinicYork UniversityPfizerUniversity of MissouriAlnylam PharmaceuticalsNovo NordiskMyoKardiaMcMaster UniversityDaiichi Sankyo EuropeGilead SciencesWeill Cornell Medical CollegeCSL BehringEli Lilly and CompanyAstraZenecaEdwards LifesciencesAmgenSanofiAmerican Heart Association
KeywordsMedicineTicagrelorAspirinBypass graftingArteryPlaceboInternal medicineCoronary artery bypass surgeryCardiologyPlatelet aggregation inhibitorRandomized controlled trialSurgeryClopidogrel

Abstract

fetched live from OpenAlex

inhibitor, ticagrelor, to low-dose aspirin for 1 year is associated with a reduction in graft failure, particularly saphenous vein grafts, at the expense of an increased risk of clinically important bleeding. As the risk of thrombotic graft failure and ischaemic events is highest early after CABG surgery, a better risk-to-benefit profile may be attained with short-term dual antiplatelet therapy followed by single antiplatelet therapy. The One Month Dual Antiplatelet Therapy With Ticagrelor in Coronary Artery Bypass Graft Patients (ODIN) trial is a prospective, randomised, double-blind, placebo-controlled, international, multicentre study of 700 subjects that will evaluate the effect of short-term dual antiplatelet therapy with ticagrelor plus low-dose aspirin after CABG in patients with CCS. Patients will be randomised 1:1 to ticagrelor 90 mg twice daily or matching placebo, in addition to aspirin 75-150 mg once daily for 1 month; after the first month, antiplatelet therapy will be continued with aspirin alone. The primary endpoint is a hierarchical composite of all-cause death, stroke, myocardial infarction, revascularisation and graft failure at 1 year. The key secondary endpoint is a hierarchical composite of all-cause death, stroke, myocardial infarction, Bleeding Academic Research Consortium (BARC) type 3 bleeding, revascularisation and graft failure at 1 year (net clinical benefit). ODIN will report whether the addition of ticagrelor to low-dose aspirin for 1 month after CABG reduces ischaemic events and provides a net clinical benefit in patients with CCS. (ClinicalTrials.gov: NCT05997693).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.033
Threshold uncertainty score0.369

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.274
Teacher spread0.233 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations11
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueEuroInterventionSame topicAntiplatelet Therapy and Cardiovascular DiseasesFrench-language works237,207